QuidelOrtho Corporation (QDEL) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

QuidelOrtho Corporation (QDEL) Healthcare & Pipeline Overview

QuidelOrtho Corporation focuses on diagnostic testing technologies, operating through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics. The company serves a global market, providing instruments and tests for hospitals, labs, and clinics, positioning itself as a key player in the healthcare diagnostics sector.

What Is the Investment Thesis for QDEL?

QuidelOrtho Corporation presents a mixed investment thesis. The company's diverse diagnostic product portfolio and global presence offer stability, while its focus on point-of-care and molecular diagnostics aligns with growing trends in healthcare. However, the company's negative profit margin of -45.6% raises concerns about profitability. Future growth hinges on successful product innovation, regulatory approvals, and expansion into new markets. Investors should closely monitor the company's ability to improve profitability and capitalize on growth opportunities in the diagnostics market. The company's beta of 0.92 suggests lower volatility compared to the broader market.

Based on FMP financials and quantitative analysis

QDEL Key Highlights

QuidelOrtho operates in four key business units: Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics, providing a diversified revenue stream.

• The company has a global presence, operating in North America, Europe, the Middle East, Africa, China, and internationally.
• QuidelOrtho serves a wide range of customers, including hospitals, clinical laboratories, urgent care clinics, and pharmacies.
• The company's gross margin stands at 56.6%, indicating a strong ability to control production costs.
• QuidelOrtho's market capitalization is $829M as of 2026-05-10.

Who Are QDEL's Competitors?

QDEL is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are QDEL's Key Strengths?

Diverse product portfolio across multiple diagnostic segments.

• Global presence with established distribution networks.
• Strong brand reputation in the diagnostics market.
• Focus on innovation and new product development.

What Are QDEL's Weaknesses?

Negative profit margin.

• Dependence on regulatory approvals for new products.
• Exposure to competition from larger diagnostic companies.
• Potential for product recalls or liability claims.

What Could Drive QDEL Stock Higher?

Regulatory approvals for new diagnostic tests.

• Expansion of distribution network in emerging markets.
• Development and launch of new point-of-care diagnostics.
• Strategic acquisitions to expand product portfolio.

What Are the Key Risks for QDEL?

Financial-distress signal — its Altman Z-Score of -0.10 sits in the distress zone (elevated bankruptcy risk).

• Negative return on equity (-49.9%) — the business is not currently generating profit on shareholder capital.
• Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
• Intense competition from established diagnostic companies.
• Changes in healthcare regulations and reimbursement policies.
• Economic downturns affecting healthcare spending.
• Negative profit margin impacting financial performance.
• Product recalls or liability claims.

What Are the Growth Opportunities for QDEL?

• Expansion in Point-of-Care Diagnostics: The point-of-care diagnostics market is experiencing rapid growth due to the increasing demand for rapid and convenient testing solutions. QuidelOrtho can capitalize on this trend by developing and commercializing new point-of-care tests for infectious diseases, cardiac markers, and other critical conditions. This market is projected to reach $40 billion by 2030, offering a substantial growth opportunity for QuidelOrtho.
• Molecular Diagnostics Growth: The molecular diagnostics market is driven by advancements in PCR and other molecular technologies. QuidelOrtho can expand its presence in this market by developing and launching new molecular diagnostic assays for infectious diseases, oncology, and genetic testing. The global molecular diagnostics market is expected to reach $15 billion by 2028, presenting a significant growth opportunity.
• Geographic Expansion: QuidelOrtho has the opportunity to expand its presence in emerging markets, such as China and India, where healthcare spending is increasing and the demand for diagnostic testing is growing. By establishing strategic partnerships and expanding its distribution network, QuidelOrtho can tap into these high-growth markets. These markets are expected to grow at a CAGR of 8-10% over the next five years.
• Strategic Acquisitions: QuidelOrtho can pursue strategic acquisitions to expand its product portfolio, enter new markets, and gain access to new technologies. By acquiring companies with complementary products and technologies, QuidelOrtho can strengthen its competitive position and accelerate its growth. Potential acquisition targets include companies specializing in niche diagnostic areas.
• Development of Novel Diagnostic Tests: QuidelOrtho can invest in research and development to develop novel diagnostic tests for emerging diseases and unmet medical needs. By focusing on innovative technologies and addressing critical healthcare challenges, QuidelOrtho can create new revenue streams and establish itself as a leader in the diagnostics market. Focus areas include rapid detection of antibiotic-resistant bacteria and early detection of cancer biomarkers.

What Are QDEL's Competitive Advantages?

• Established brand reputation in the diagnostics market.
• Extensive product portfolio covering a wide range of diagnostic testing needs.
• Global presence with operations in North America, Europe, the Middle East, Africa, and China.
• Strong distribution network with direct sales force and distributors.

What Does QDEL Do?

Founded in 1979 and headquartered in San Diego, California, QuidelOrtho Corporation develops and manufactures diagnostic testing technologies across the healthcare continuum. The company's operations are divided into four key business units: Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics. The Labs business unit offers clinical chemistry and immunoassay laboratory instruments and tests used to evaluate health and manage patients. The Transfusion Medicine business unit provides immunohematology instruments and tests for blood typing and donor screening. The Point-of-Care business unit focuses on rapid diagnostic tests for various settings. The Molecular Diagnostics business unit offers PCR thermocyclers and amplification systems. QuidelOrtho sells its products through a direct sales force and a network of distributors, serving physician offices, hospitals, clinical and reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers. The company operates in North America, Europe, the Middle East, Africa, China, and other international markets, addressing both professional and over-the-counter testing needs.

What Products and Services Does QDEL Offer?

• Develops clinical chemistry laboratory instruments and tests.
• Manufactures immunoassay laboratory instruments and tests.
• Creates testing products to detect and monitor disease progression.
• Offers immunohematology instruments and tests for blood typing.
• Provides donor screening instruments and tests for infectious diseases.
• Develops point-of-care tests for rapid results.
• Offers polymerase chain reaction thermocyclers and analyzers.

How Does QDEL Make Money?

• Develops and manufactures diagnostic testing technologies.
• Sells products directly to end users through a direct sales force.
• Distributes products through a network of distributors.
• Generates revenue from the sale of instruments, tests, and related services.

What Industry Does QDEL Operate In?

QuidelOrtho Corporation operates in the medical instruments and supplies industry, which is characterized by technological advancements, increasing demand for diagnostic testing, and stringent regulatory requirements. The global diagnostics market is expected to grow, driven by factors such as an aging population, the rising prevalence of chronic diseases, and the increasing adoption of point-of-care testing. QuidelOrtho competes with companies offering similar diagnostic solutions, such as EWTX: Edgewise Therapeutics, Inc., requiring continuous innovation and strategic partnerships to maintain market share.

Who Are QDEL's Key Customers?

• Physician offices
• Clinical laboratories
• Reference laboratories
• Urgent care clinics
• Universities
• Retail clinics
• Pharmacies
• Wellness screening centers
• Blood banks
• Donor centers

Company Profile

QuidelOrtho Corporation operates in the Medical - Specialties industry within the Healthcare sector. It is headquartered in San Diego, US. The company is led by CEO Brian J. Blaser. QDEL has traded publicly since 1991.

QuidelOrtho Corporation Financial Trajectory

QuidelOrtho Corporation (QDEL) reported $630.9M in revenue for Q2 FY2026, reflecting 1.8% growth compared to the prior quarter. The company recorded a net loss of $92.9M, with diluted EPS of $-1.36. Quarter-over-quarter revenue has been mixed, typical for a small-cap company operating in Healthcare. Across the four most recent quarters, QDEL averaged $-3.85 in diluted EPS.

How QuidelOrtho Corporation Is Valued

QuidelOrtho Corporation carries a market capitalization of $829M, placing it in the small-cap category. Analyst price targets span from $12.00 to $12.50, with a consensus of $12.25. At the current price of $12.15, that implies approximately 1% upside potential. Relative to its peer group, QDEL's quantitative score of 18/100 is below the peer average of 60/100.

Return on equity for QuidelOrtho Corporation stands at -49.9%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 0.5%, showing how much profit it generates from its asset base. QDEL trades at a trailing price-to-earnings ratio of 5.97, below the Healthcare sector average of ~21.50x. A current ratio of 1.43 indicates the company holds enough short-term assets to cover its near-term obligations.

QuidelOrtho Corporation's Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -0.10 places it in the distress zone, a signal of elevated financial risk.

QuidelOrtho Corporation has beaten Wall Street's EPS estimate in 7 of its last 8 reported quarters — a consistent record of delivering on expectations. Reported results have landed about 1033.8% above estimates on average.

Over the past six months, QuidelOrtho Corporation insiders filed 88 SEC Form 4 transactions — 36 sales and 52 purchases. On net that is roughly 673K shares acquired (about $1.1M) — insiders putting money in tends to read as conviction.

QDEL Financials

QDEL Latest News

QDEL Analyst Consensus

QDEL MoonshotScore

QDEL Healthcare Stock FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources